No products in the cart.
#VisualAbstract: Nivolumab plus ipilimumab is safe and effective for the treatment of advanced melanoma (CheckMate 218)
Click to read the study in Melanoma Research.
Tag: Nivolumab
Nivolumab and cabozantinib superior to sunitinib for advanced renal-cell carcinoma
1. The combination of nivolumab and cabozantinib was superior to sunitinib in untreated advanced renal-cell carcinoma 2. The combination treatment ...
#VisualAbstract: Nivolumab plus ipilimumab increases overall survival in patients with malignant pleural mesothelioma
1. Median overall survival in the nivolumab plus ipilimumab group (18.1 months) was substantially greater than in the chemotherapy group (14.1 ...
Nivolumab plus ipilimumab increases overall survival in patients with malignant pleural mesothelioma
1. Median overall survival in the nivolumab plus ipilimumab group (18.1 months) was substantially greater than in the chemotherapy group ...
#VisualAbstract: Prognosis for advanced melanoma has improved between 2013 to 2017 for patients in the Netherlands
Click to read the study in the European Journal of Cancer.
Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor–Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors
1. The glucocorticoid-induced TNF receptor-related protein agonist, BMS-986156, is safe and tolerable as monotherapy and in combination with nivolumab. Evidence ...
2 Minute Medicine Rewind November 11, 2019
Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical ...
#VisualAbstract: Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer
1. Nivolumab and bevacizumab combination therapy appears to be efficacious in relapsed epithelial ovarian cancer, especially in patients with platinum-sensitive ...
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial
1. Nivolumab and bevacizumab combination therapy appears to be efficacious in relapsed epithelial ovarian cancer, especially in patients with platinum-sensitive ...
